Myeloma Minute: MRD Testing On Its Way


November 3, 2016

NCCN Endorses MRD Testing: What Does This Mean for Patients?

The NCCN’s endorsement this week of minimal residual testing is good news for myeloma patients. But what’s the best method for measuring these tiny cancer clones? In his blog, IMF Chairman Dr. Brian Durie spells out the very important differences between the two recommended MRD tests and declares one to be the decisive winner. To read Dr. Durie’s blog, click HERE.

Ray Romano to Host IMF 10th Annual Comedy Celebration - Nov. 5

The IMF’s annual Comedy Celebration will take place this Saturday, November 5 at the Wilshire Ebell Theatre. Actor and comedian Ray Romano returns as “Everybody’s Most-Loved Host,” with featured performers Bill Burr, Jeff Garlin, Dom Irrera, Larry Miller, Kevin Nealon, JB Smoove, and Fred Willard. Proceeds from the event benefit the Peter Boyle Research Fund and support the Black Swan Research Initiative® (BSRI). Renowned actor Peter Boyle died in 2006 after a four-year battle with myeloma. In celebration of the event’s 10th anniversary, the event will honor Loraine Alterman Boyle for her extraordinary work as the event chair over the past 10 years. Since the annual Comedy Celebration began in 2007, the event has raised close to $6 million to support myeloma research. The evening will include a pre-show cocktail reception and silent auction, and a post-show party featuring a live swing band and dancing for VIP ticket holders. 

Pre-register for FREE for the Next "Living Well with Myeloma" Teleconference: Pre-ASH Highlights

Join Dr. Brian G.M. Durie as he moderates “Pre-ASH – What Patients & Caregivers Can Look Forward To,” a teleconference on Thursday, November 17, 2016 at 4:00 p.m. PT / 7:00 p.m. ET. Dr. Durie will focus on issues in the myeloma community that are relevant to this year’s American Society of Hematology (ASH) Conference, which convenes in San Diego on December 2–5, 2016. 

Myeloma Matrix 2.0: Clinical Trial Search Tool Now Released

Recently redesigned, the Myeloma Matrix 2.0: Smart Search is an important resource on that lists myeloma drugs currently under development and tracks them from discovery to approval. Its new large-print grid and color-coded format provides detailed information about clinical trials that is easy to understand for patients and caregivers. With this 2.0 release, trials are searchable by phase and browsable by the status of therapy needs: newly diagnosed, smoldering, maintenance, or relapse/refractory. The trial information provided includes such details as the location and dates of the trial, its study design, arms, and eligibility criteria. One can cross-reference similar trials as well. Learn about the latest additions to clinical trials and also about which ones are currently accruing patients. With this up-to-the-minute information, patients can gain knowledge about myeloma drugs in all stages of development—from Pre-Clinical (laboratory-only) to FDA-Approved. Visit the Myeloma Matrix 2.0: Smart Search at

We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb

Subscribe to the Myeloma Minute

Source URL: